Retrospective Cohort Study
Copyright ©The Author(s) 2020.
World J Gastroenterol. Nov 28, 2020; 26(44): 6993-7004
Published online Nov 28, 2020. doi: 10.3748/wjg.v26.i44.6993
Table 4 Univariate analysis assessing the relative risk (95%CI) of inflammatory bowel disease patients under treatment who developed active tuberculosis from a referral center
Variable
Total, n (%)
Active tuberculosis, n (%)
RR (95%CI)
P value
Sex0.027
Female188 (62.5)2 (1,1)1.0
Male113 (37.5)6 (5.3)4.99 (1.02-24.3)
Age (yr)0.158
18-40185 (61.5)3 (1.6)1.0
41-91116 (38.5)5 (4.3)2.66 (0.65-10.91)
IBD type0.487
RCU186 (61.8)4 (2.2)1.0
CD115 (38.2)4 (3.5)1.61 (0.41-6.34)
Latent TB< 0.001
No276 (93.2)5 (1.8)1.0
Yes20 (6.8)3 (15.0)8.28 (2.13-32.18)
Azathioprine0.013
No199 (66.1)2 (1.0)1.0
Yes102 (33.0)6 (5.9)5.85 (1.20-28.48)
Anti-TNFα0.034
No240 (79.7)4 (1.7)1.0
Yes61 (20.3)4 (6.5)3.93 (1.01-15.29)
Aza + Anti-TNFα< 0.001
No271 (90.0)4 (1.5)1.0
Yes30 (10.0)4 (13.3)9.03 (2.38-34.28)